Skip to main content

Advertisement

SpringerLink
Log in

See-and-Treat Approaches to Cervical Cancer Prevention for HIV-Infected Women

  • Published:
Current HIV/AIDS Reports Aims and scope Submit manuscript

Abstract

Cervical cancer remains the second commonest cancer among women worldwide, and more than 85% of the global burden of this disease occurs in the developing world. HIV-infected women have a higher likelihood of developing persistent high-risk human papillomavirus (HPV) infection, precancer, and invasive cervical cancer than seronegative women. Although highly effective primary and secondary prevention strategies are currently available, they remain inaccessible to the vast majority of women. Because of their simplicity and affordability, see-and-treat cervical cancer screening modalities have the potential to substantially improve women’s access to cancer prevention, as well as to create much needed infrastructure for future molecular-based cervical screening and HPV vaccination programs. Additional data addressing the effectiveness of see-and-treat approaches for HIV-infected women are urgently needed. Studies informing best practice guidelines on when to start, when to stop, and how frequently to screen HIV-infected women within the see-and-treat paradigm would be of great value.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. IARC. Cancer incidence and mortality worldwide in 2008. In: p. Available at: http://globocan.iarc.fr/factsheets/cancers/cervix.asp.

  2. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.

    Article  PubMed  Google Scholar 

  3. • Sahasrabuddhe VV, Bhosale RA, Kavatkar AN et al. Comparison of visual inspection with acetic acid (VIA) and cervical cytology to detect high grade cervical neoplasia among HIV-infected women in India. Int J Cancer 2011. doi:10.1002/ijc.25971.

  4. Gakidou E, Nordhagen S, Obermeyer Z. Coverage of cervical cancer screening in 57 countries: low average levels and large inequalities. PLoS Med. 2008;5:e132.

    Article  PubMed  Google Scholar 

  5. Mandelblatt JS, Lawrence WF, Gaffikin L, et al. Costs and benefits of different strategies to screen for cervical cancer in less-developed countries. J Natl Cancer Inst. 2002;94:1469–83.

    PubMed  Google Scholar 

  6. de Sanjose S, Quint WG, Alemany L, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010;11:1048–56.

    Article  PubMed  Google Scholar 

  7. Castellsague X. Natural history and epidemiology of HPV infection and cervical cancer. Gynecol Oncol. 2008;110:S4–7.

    Article  PubMed  Google Scholar 

  8. Munoz N, Bosch FX, de Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003;348:518–27.

    Article  PubMed  Google Scholar 

  9. Smith JS, Lindsay L, Hoots B, et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer. 2007;121:621–32.

    Article  PubMed  CAS  Google Scholar 

  10. Singh DK, Anastos K, Hoover DR, et al. Human papillomavirus infection and cervical cytology in HIV-infected and HIV-uninfected Rwandan women. J Infect Dis. 2009;199:1851–61.

    Article  PubMed  Google Scholar 

  11. Denny L, Boa R, Williamson AL, et al. Human papillomavirus infection and cervical disease in human immunodeficiency virus-1-infected women. Obstet Gynecol. 2008;111:1380–7.

    Article  PubMed  Google Scholar 

  12. Kojic EM, Cu-Uvin S. Update: human papillomavirus infection remains highly prevalent and persistent among HIV-infected individuals. Curr Opin Oncol. 2007;19:464–9.

    Article  PubMed  Google Scholar 

  13. Sahasrabuddhe VV, Mwanahamuntu MH, Vermund SH, et al. Prevalence and distribution of HPV genotypes among HIV-infected women in Zambia. Br J Cancer. 2007;96:1480–3.

    PubMed  CAS  Google Scholar 

  14. Moscicki AB, Schiffman M, Kjaer S, Villa LL. Chapter 5: Updating the natural history of HPV and anogenital cancer. Vaccine. 2006;24 Suppl 3:S3/42-51.

    PubMed  Google Scholar 

  15. Ho GY, Bierman R, Beardsley L, et al. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med. 1998;338:423–8.

    Article  PubMed  CAS  Google Scholar 

  16. Sankaranarayanan R, Thara S, Esmy PO, Basu P. Cervical cancer: screening and therapeutic perspectives. Med Princ Pract. 2008;17:351–64.

    Article  PubMed  Google Scholar 

  17. Omar T, Schwartz S, Hanrahan C, et al. Progression and regression of premalignant cervical lesions in HIV-infected women from Soweto: a prospective cohort. AIDS. 2011;25:87–94.

    Article  PubMed  Google Scholar 

  18. Ngoma T, Muwonge R, Mwaiselage J, et al. Evaluation of cervical visual inspection screening in Dar es Salaam, Tanzania. Int J Gynaecol Obstet. 2010;109:100–4.

    Article  PubMed  Google Scholar 

  19. Mwanahamuntu MH, Sahasrabuddhe VV, Pfaendler KS, et al. Implementation of ‘see-and-treat’ cervical cancer prevention services linked to HIV care in Zambia. AIDS. 2009;23:N1–5.

    Article  PubMed  Google Scholar 

  20. Blumenthal P, Gaffikin L, Deganus S, et al. Cervical cancer prevention: safety, acceptability, and feasibility of a single-visit approach in Accra, Ghana. Am J Obstet Gynecol. 2007;196:407.e1–9.

    Article  Google Scholar 

  21. Sankaranarayanan R, Rajkumar R, Esmy PO, et al. Effectiveness, safety and acceptability of ‘see and treat’ with cryotherapy by nurses in a cervical screening study in India. Br J Cancer. 2007;96:738–43.

    Article  PubMed  CAS  Google Scholar 

  22. Sangwa-Lugoma G, Mahmud S, Nasr SH, et al. Visual inspection as a cervical cancer screening method in a primary health care setting in Africa. Int J Cancer. 2006;119:1389–95.

    Article  PubMed  CAS  Google Scholar 

  23. Goldie SJ, Gaffikin L, Goldhaber-Fiebert JD, et al. Cost-effectiveness of cervical-cancer screening in five developing countries. N Engl J Med. 2005;353:2158–68.

    Article  PubMed  CAS  Google Scholar 

  24. IARC. Screening tests. Lyon: IARCPress; 2005.

    Google Scholar 

  25. Basu P, Sankaranarayanan R, Mandal R et al. Evaluation of downstaging in the detection of cervical neoplasia in Kolkata, India. Int J Cancer. 2002; 100:92–6

    Google Scholar 

  26. Sankaranarayanan R, Basu P, Wesley RS, et al. Accuracy of visual screening for cervical neoplasia: Results from an IARC multicentre study in India and Africa. Int J Cancer. 2004;110:907–13.

    Article  PubMed  CAS  Google Scholar 

  27. Arbyn M, Sankaranarayanan R, Muwonge R, et al. Pooled analysis of the accuracy of five cervical cancer screening tests assessed in eleven studies in Africa and India. Int J Cancer. 2008;123:153–60.

    Article  PubMed  CAS  Google Scholar 

  28. Akinwuntan AL, Adesina OA, Okolo CA, et al. Correlation of cervical cytology and visual inspection with acetic acid in HIV-positive women. J Obstet Gynaecol. 2008;28:638–41.

    Article  PubMed  CAS  Google Scholar 

  29. Martin-Hirsch PP, Paraskevaidis E, Bryant A et al. Surgery for cervical intraepithelial neoplasia. Cochrane database of systematic reviews 2010:CD001318.

  30. Sankaranarayanan R, Keshkar V, Kothari A, et al. Effectiveness and safety of loop electrosurgical excision procedure for cervical neoplasia in rural India. Int J Gynaecol Obstet. 2009;104:95–9.

    Article  PubMed  Google Scholar 

  31. Luciani S, Gonzales M, Munoz S, et al. Effectiveness of cryotherapy treatment for cervical intraepithelial neoplasia. Int J Gynaecol Obstet. 2008;101:172–7.

    Article  PubMed  Google Scholar 

  32. Rema P, Suchetha S, Thara S, et al. Effectiveness and safety of loop electrosurgical excision procedure in a low-resource setting. Int J Gynaecol Obstet. 2008;103:105–10.

    Article  PubMed  Google Scholar 

  33. Chirenje ZM, Rusakaniko S, Akino V, Mlingo M. A randomised clinical trial of loop electrosurgical excision procedure (LEEP) versus cryotherapy in the treatment of cervical intraepithelial neoplasia. J Obstet Gynaecol. 2001;21:617–21.

    Article  PubMed  CAS  Google Scholar 

  34. Mitchell MF, Tortolero-Luna G, Cook E, et al. A randomized clinical trial of cryotherapy, laser vaporization, and loop electrosurgical excision for treatment of squamous intraepithelial lesions of the cervix. Obstet Gynecol. 1998;92:737–44.

    Article  PubMed  CAS  Google Scholar 

  35. Arbyn M, Kyrgiou M, Simoens C, et al. Perinatal mortality and other severe adverse pregnancy outcomes associated with treatment of cervical intraepithelial neoplasia: meta-analysis. BMJ. 2008;337:a1284.

    Article  PubMed  CAS  Google Scholar 

  36. Crane JM. Pregnancy outcome after loop electrosurgical excision procedure: a systematic review. Obstet Gynecol. 2003;102:1058–62.

    Article  PubMed  Google Scholar 

  37. Chirenje ZM, Rusakaniko S, Akino V, et al. Effect of HIV disease in treatment outcome of cervical squamous intraepithelial lesions among Zimbabwean Women. J Low Genit Tract Dis. 2003;7:16–21.

    Article  PubMed  CAS  Google Scholar 

  38. Massad LS, Fazzari MJ, Anastos K, et al. Outcomes after treatment of cervical intraepithelial neoplasia among women with HIV. J Low Genit Tract Dis. 2007;11:90–7.

    Article  PubMed  Google Scholar 

  39. Lima MI, Tafuri A, Araujo AC, et al. Cervical intraepithelial neoplasia recurrence after conization in HIV-positive and HIV-negative women. Int J Gynaecol Obstet. 2009;104:100–4.

    Article  PubMed  Google Scholar 

  40. Brockmeyer AD, Wright JD, Gao F, Powell MA. Persistent and recurrent cervical dysplasia after loop electrosurgical excision procedure. Am J Obstet Gynecol. 2005;192:1379–81.

    Article  PubMed  Google Scholar 

  41. Wright Jr TC, Koulos J, Schnoll F, et al. Cervical intraepithelial neoplasia in women infected with the human immunodeficiency virus: outcome after loop electrosurgical excision. Gynecol Oncol. 1994;55:253–8.

    Article  PubMed  Google Scholar 

  42. Leguevaque P, Motton S, Decharme A, et al. Predictors of recurrence in high-grade cervical lesions and a plan of management. Eur J Surg Oncol. 2010;36:1073–9.

    PubMed  CAS  Google Scholar 

  43. • Chamot E, Kristensen S, Stringer JS, Mwanahamuntu MH. Are treatments for cervical precancerous lesions in less-developed countries safe enough to promote scaling-up of cervical screening programs? A systematic review. BMC women’s health 2010; 10:11.

  44. Kietpeerakool C, Suprasert P, Srisomboon J. Outcome of loop electrosurgical excision for HIV-positive women in a low-resource outpatient setting. Int J Gynaecol Obstet. 2009;105:10–3.

    Article  PubMed  Google Scholar 

  45. Pfaendler KS, Mwanahamuntu MH, Sahasrabuddhe VV, et al. Management of cryotherapy-ineligible women in a “screen-and-treat” cervical cancer prevention program targeting HIV-infected women in Zambia: lessons from the field. Gynecol Oncol. 2008;110:402–7.

    Article  PubMed  Google Scholar 

  46. van Bogaert LJ. Age at diagnosis of preinvasive and invasive cervical neoplasia in South Africa: HIV-positive versus HIV-negative women. Int J Gynaecol Obstet. 2011;21:363–6.

    Google Scholar 

  47. ACOG. Cervical ctyology screening. 2009.

  48. WHO. Comprehensive cervical cancer control: A guide to essential practice. WHO; 2006.

  49. Kim JJ, Leung GM, Woo PP, Goldie SJ. Cost-effectiveness of organized versus opportunistic cervical cytology screening in Hong Kong. J Public Health. 2004;26:130–7.

    Article  Google Scholar 

  50. Goldie SJ, Kuhn L, Denny L, et al. Policy analysis of cervical cancer screening strategies in low-resource settings: clinical benefits and cost-effectiveness. JAMA. 2001;285:3107–15.

    Article  PubMed  CAS  Google Scholar 

  51. Cremer M, Conlisk E, Maza M et al. Adequacy of visual inspection with acetic acid in women of advancing age. Int J Gynaecol Obstet. 2011;113(1):68–71.

    Google Scholar 

  52. Adam Y, van Gelderen CJ, Newell K. ‘Look and Lletz’–a Chris Hani Baragwanath Hospital experience. S Afr Med J. 2008;98:119–22.

    PubMed  CAS  Google Scholar 

  53. Denny L, Kuhn L, De Souza M, et al. Screen-and-treat approaches for cervical cancer prevention in low-resource settings: a randomized controlled trial. JAMA. 2005;294:2173–81.

    Article  PubMed  CAS  Google Scholar 

  54. Quinn TC, Wawer MJ, Sewankambo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med. 2000;342:921–9.

    Article  PubMed  CAS  Google Scholar 

  55. Wright Jr TC, Subbarao S, Ellerbrock TV, et al. Human immunodeficiency virus 1 expression in the female genital tract in association with cervical inflammation and ulceration. Am J Obstet Gynecol. 2001;184:279–85.

    Article  PubMed  Google Scholar 

  56. Chung M, McKenzie K, Richardson B et al. Cervical HIV-1 RNA shedding after cryotherapy among HIV+ women with cervical intraepithelial neoplasia 2/3. In: 18th Conference on Retroviruses and Opportunistic Infections. Boston, USA: 2011.

  57. Tsu VD, Levin CE. Making the case for cervical cancer prevention: what about equity? Reprod Health Matters. 2008;16:104–12.

    Article  PubMed  Google Scholar 

  58. Denny L, Quinn M, Sankaranarayanan R. Chapter 8: Screening for cervical cancer in developing countries. Vaccine. 2006;24 Suppl 3:S3/71-7.

    PubMed  Google Scholar 

  59. Denny L, Kuhn L, Hu CC, et al. Human papillomavirus-based cervical cancer prevention: long-term results of a randomized screening trial. J Natl Cancer Inst. 2010;102:1557–67.

    Article  PubMed  Google Scholar 

  60. • Kuhn L, Wang C, Tsai WY et al. Efficacy of human papillomavirus-based screen-and-treat for cervical cancer prevention among HIV-infected women. AIDS 2010; 24:2553–61.

    Article  PubMed  Google Scholar 

  61. • Sankaranarayanan R, Nene BM, Shastri SS et al. HPV screening for cervical cancer in rural India. N Engl J Med 2009; 360:1385–94.

    Article  PubMed  CAS  Google Scholar 

  62. • Lu B, Kumar A, Castellsague X, Giuliano AR. Efficacy and safety of prophylactic vaccines against cervical HPV infection and diseases among women: a systematic review & meta-analysis. BMC infectious diseases 2011; 11:13.

    Article  PubMed  Google Scholar 

  63. FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. New Eng J Med. 2007;356:1915–27.

    Article  Google Scholar 

  64. Harper DM, Franco EL, Wheeler CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet. 2006;367:1247–55.

    Article  PubMed  CAS  Google Scholar 

  65. Harper DM, Franco EL, Wheeler C, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet. 2004;364:1757–65.

    Article  PubMed  CAS  Google Scholar 

  66. • Levin MJ, Moscicki AB, Song LY et al. Safety and immunogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine in HIV-infected children 7 to 12 years old. J Acquir Immue Defic Syndr. 2010; 55:197–204.

    Article  PubMed  Google Scholar 

Download references

Acknowledgment

Support was provided by the National Institutes of Health through the International Clinical Research Fellows Program at Vanderbilt University (R24 TW007988), as well as through a K24 award (K24 AI066884). The funding agency played no role in the preparation of this manuscript.

Disclosure

No potential conflicts of interest relevant to this article were reported.

Author information

Authors and Affiliations

  1. University of Alabama at Birmingham School of Medicine, Birmingham, AL, USA

    Carla J. Chibwesha

  2. Centre for Infectious Disease Research in Zambia, PO Box 34681, Lusaka, Zambia

    Carla J. Chibwesha

  3. Alpert Medical School, Brown University, Providence, RI, USA

    Susan Cu-Uvin

Authors
  1. Carla J. Chibwesha
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Susan Cu-Uvin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Carla J. Chibwesha.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chibwesha, C.J., Cu-Uvin, S. See-and-Treat Approaches to Cervical Cancer Prevention for HIV-Infected Women. Curr HIV/AIDS Rep 8, 192–199 (2011). https://doi.org/10.1007/s11904-011-0084-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11904-011-0084-6

Keywords

Search

Navigation